LLY · 8-K · 20261029PR000104
Acquired IPR&D Charges
ELI LILLY & Co · 2026-10-29 · Importance 71 · Surprise 82 · From source text
Lilly recorded $4.181 billion of acquired IPR&D charges in Q3 2026, compared with $656 million in Q3 2025. The Q3 charges primarily related to the acquisitions of AtaiBeckley and Curevo. Nine-month acquired IPR&D charges totaled $7.541 billion, compared with $2.381 billion in the prior-year period; Q3 reported and non-GAAP EPS included $4.57 per share of acquired IPR&D charges versus $0.71 a year earlier.
Key facts
- Lilly recognized Q3 2026 acquired IPR&D charges of $4.2 billion, compared with $656 million in Q3 2025; the 2026 charges primarily related to the AtaiBeckley and Curevo acquisitions. source
- Lilly completed its acquisition of AtaiBeckley in Q3 2026 to advance therapies for treatment-resistant depression and other mental health conditions. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -15.4% | Lilly recognized Q3 2026 acquired IPR&D charges of $4.2 billion, compared with $656 million in Q3 2025; the 2026 charges primarily related… |